Este reporte evalua la eficacia y seguridad del plasma convaleciente más tratamiento estándar (CP + SoC) en comparación con solo tratamiento estándar (SoC) en pacientes hospitalizados por COVID-19 moderado a severo que aún no requieren ventilador mecánico.

OBJECTIVES: To assess the efficacy and safety of convalescent plasma plus standard of care (CP + SoC) compared with standard of care (SoC) alone in patients hospitalized for moderate to severe COVID-19 who do not yet require mechanical ventilation. METHODS: Phase 2 randomized, parallel-group, randomized, open-label, controlled, superiority, single-center clinical trial. This clinical trial has been registered in REPEC with the following ID: 013-20. Hospitalized adult patients with moderate to severe COVID-19 were enrolled. The allocation ratio was 1:1 in a variable-size permuted block randomization scheme. The primary outcome was death 28 days after the intervention. Secondary outcomes were mortality at 14 and 56 days, time to death at 56 days, time in the ICU at 28 days, time on a mechanical ventilator at 28 days, frequency of adverse events, and frequency of serious adverse events. RES...

El objetivo de este reporte es determinar el nivel de respuesta humoral alcanzado tras la aplicación de la tercera dosis de refuerzo de BNT162b2 seguido de un régimen completo de BBIBP-CorV, evaluar los factores asociados a mayores anticuerpos IgG anti-SARS-CoV-2 y reportar los eventos adversos a la aplicación de este refuerzo mixto.

Background: The inactivated virus vaccine, BBIBP-CorV, was principally distributed across low- and middle-income countries as primary vaccination strategy to prevent poor COVID-19 outcomes. Limited information is available regarding its effect on heterologous boosting. We aim to evaluate the immunogenicity and reactogenicity of a third booster dose of BNT162b2 following a double BBIBP-CorV regime. Methods: We conducted a cross-sectional study among healthcare providers from several healthcare facilities of the Seguro Social de Salud del Perú - ESSALUD. We included participants two-dose BBIBPCorV vaccinated who presented a three-dose vaccination card at least 21 days passed since the vaccinees received their third dose and were willing to provide written informed consent. Antibodies were determined using LIAISON SARS-CoV-2 TrimericS IgG (DiaSorin Inc., Stillwater, USA). Factors potential...

Objective: To estimate the prevalence of post-vaccination seropositivity against SARS-CoV-2 and identify its predictors in Peruvian Social Health Insurance (EsSalud) personnel in 2021. Methods: We conducted a cross-sectional study in a representative simple stratified sample of EsSalud workers. We evaluated IgG anti-SARS-CoV-2 antibodies response (seropositivity) by passive (previous infection) and active immunization (vaccination), and epidemiological and occupational variables obtained by direct interview and a data collection form. Descriptive and inferential statistics were used with correction of sample weights adjusted for non-response rate, and crude and adjusted odds ratio (OR) and geometric mean ratio (GMR) with their respective 95% confidence intervals (95%CI) were estimated. Results: We enrolled 1077 subjects. Seropositivity was 67.4% (95%CI: 63.4–71.1). Predictors of seropo...

Este reporte pretende estimar la prevalencia de seropositividad post-vacunación contra SARS-CoV-2 e identificar sus predictores en personal del Seguro Social de Salud (EsSalud) durante el 2021.